Erlotinib Treatment Beyond Progression in EGFR Mutant NSCLC

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2014
The purpose of this study is to determine whether continuing erlotinib beyond disease progression in combination with chemotherapy is beneficial for NSCLC patients who have EGFR mutant disease or who have responded to EGFR TKI.
Epistemonikos ID: 1a1b6a2f0760bc7569ec777a9703d7cc25c52bda
First added on: May 11, 2024